UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 426

Sortiert nach

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

The New England journal of medicine, 2021-03, Vol.384 (12), p.1125-1135

2021

Link zum Volltext

Verfügbarkeit prüfen

BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?

World journal of urology, 2021-11, Vol.39 (11), p.4037-4046

2021

Link zum Volltext

Verfügbarkeit prüfen

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial

Nature medicine, 2021-12, Vol.27 (12), p.2200-2211

2021

Link zum Volltext

Verfügbarkeit prüfen

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

The New England journal of medicine, 2019-07, Vol.381 (4), p.338-348

2019

Link zum Volltext

Verfügbarkeit prüfen

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

Clinical cancer research, 2020-02, Vol.26 (4), p.764-774

2020

Link zum Volltext

Verfügbarkeit prüfen

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Nature Medicine, 2019-05, Vol.25 (5), p.751-758

2019

Link zum Volltext

Verfügbarkeit prüfen

Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic

European urology, 2020-07, Vol.78 (1), p.1-3

2020

Link zum Volltext

Verfügbarkeit prüfen

Carcinomas of an unknown primary origin--diagnosis and treatment

Nature reviews. Clinical oncology, 2011-12, Vol.8 (12), p.701-710

2011

Link zum Volltext

Verfügbarkeit prüfen

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

Clinical cancer research, 2016-12, Vol.22 (24), p.5983-5991

2016

Link zum Volltext

Verfügbarkeit prüfen

Abiraterone and Increased Survival in Metastatic Prostate Cancer

The New England journal of medicine, 2011-05, Vol.364 (21), p.1995-2005

2011

Link zum Volltext

Verfügbarkeit prüfen

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies

European urology, 2015-08, Vol.68 (2), p.228-235

2015

Link zum Volltext

Verfügbarkeit prüfen

Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma

European urology, 2015-07, Vol.68 (1), p.154-160

2015

Link zum Volltext

Verfügbarkeit prüfen

Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model

Nature communications, 2020-04, Vol.11 (1), p.1884-1884, Article 1884

2020

Link zum Volltext

Verfügbarkeit prüfen

Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer

European journal of cancer (1990), 2015-09, Vol.51 (14), p.1946-1952

2015

Link zum Volltext

Verfügbarkeit prüfen

Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth

Clinical cancer research, 2015-04, Vol.21 (7), p.1675-1687

2015

Link zum Volltext

Verfügbarkeit prüfen

Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data

European urology, 2014-04, Vol.65 (4), p.713-720

2014

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

European urology, 2018-03, Vol.73 (3), p.462-468

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301

European urology, 2015-05, Vol.67 (5), p.866-873

2015

Link zum Volltext

Verfügbarkeit prüfen

Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.438-438

2021

Link zum Volltext

Verfügbarkeit prüfen

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Therapeutic Advances in Medical Oncology, 2020, Vol.12, p.1758835920978134-1758835920978134

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 426

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(416)
Mit Volltextzugriff
(399)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Carcinomas of an unknown primary origin--diagnosis and treatment

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma

Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model

Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer

Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth

Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer

Tumor Growth Rate Provides Useful Information to Evaluate Sorafenib and Everolimus Treatment in Metastatic Renal Cell Carcinoma Patients: An Integrated Analysis of the TARGET and RECORD Phase 3 Trial Data

Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens

Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301

Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy

Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer

Suchergebnisse filtern